Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM
Key facts
- Who runs it
- Royal North Shore Hospital
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 3 Oct 2024
- Ended
- 3 Oct 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
- Record updated
- 18 November 2024
- Why it stopped
- no resources to run the trial
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients undergoing definitive external beam radiotherapy at Northern Sydney Cancer Centre
- Patients histologically proven prostate adenocarcinoma
- PSA obtained within 3 months prior to enrolment
- Pelvic lymph nodes are included for treatment for patients at stage T1c-T3b with Gleason 8-10 or prostate-specific antigen (PSA) > 20 ng/ml or pelvic lymph node positivity on conventional imaging or prostate-specific membrane antigen (PSMA) scans
- Patient must be able to have gold fiducial markers placed in the prostate
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Ability to understand and the willingness to sign a written informed consent document
- Prostate dimension that allows leaf span with tracking margin of ±8mm
Who cannot take part
- Patients with artificial Hip(s), lumbar spinal surgical rods or other large metallic pelvic implants
- Patient's dimensions >40cm as measured at the level of the prostate
- Patients with overlapping implanted gold fiducials in x-ray imaging
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Assessing the feasibility of implementing real-time multi-leaf collimator (MLC) tracking to account for the relative motion of the moving prostate tumour target and the static pelvic nodal target for high-risk prostate cancer patients. The capability of tracking for the relative motion of multiple targets will ensure that all the treatment targets receive correct dose as prescribed by the doctor and minimise side effects to the critical organs.
The 2 groups in the trial
- Stage 1: Optimise nodal treatment marginTreatment being tested
During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
Treatment: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
- Stage 2: Use treatment marginTreatment being tested
During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
Treatment: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I Feasibility Study of Accounting for Relative Motion of Multiple Targets in Prostate Cancer Radiotherapy Using Realtime Multi-leaf Collimator Adaptation and Kilovoltage (kV) Intrafraction Monitoring
- Record updated
- 18 November 2024